The estimated Net Worth of James E Deerfield Mgmt Iv, ... is at least $2.98 Million dollars as of 24 October 2019. James Iv owns over 700,000 units of Cabaletta Bio Inc stock worth over $2,982,000 and over the last 5 years James sold CABA stock worth over $0.
James has made over 1 trades of the Cabaletta Bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently James bought 700,000 units of CABA stock worth $7,700,000 on 24 October 2019.
The largest trade James's ever made was buying 700,000 units of Cabaletta Bio Inc stock on 24 October 2019 worth over $7,700,000. On average, James trades about 700,000 units every 0 days since 2019. As of 24 October 2019 James still owns at least 700,000 units of Cabaletta Bio Inc stock.
You can see the complete history of James Iv stock trades at the bottom of the page.
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport..., and James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Cabaletta Bio Inc executives and other stock owners filed with the SEC include: